KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Net Income (2016 - 2025)

Biogen (BIIB) has 17 years of Net Income data on record, last reported at -$48.9 million in Q4 2025.

  • For Q4 2025, Net Income fell 118.34% year-over-year to -$48.9 million; the TTM value through Dec 2025 reached $1.3 billion, down 20.79%, while the annual FY2025 figure was $1.3 billion, 20.79% down from the prior year.
  • Net Income reached -$48.9 million in Q4 2025 per BIIB's latest filing, down from $466.5 million in the prior quarter.
  • Across five years, Net Income topped out at $1.1 billion in Q3 2022 and bottomed at -$141.2 million in Q3 2023.
  • Average Net Income over 5 years is $443.7 million, with a median of $408.1 million recorded in 2021.
  • Peak YoY movement for Net Income: surged 1534.73% in 2022, then tumbled 118.34% in 2025.
  • A 5-year view of Net Income shows it stood at -$38.3 million in 2021, then soared by 1534.73% to $549.5 million in 2022, then crashed by 46.93% to $291.6 million in 2023, then fell by 8.54% to $266.7 million in 2024, then crashed by 118.34% to -$48.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$48.9 million in Q4 2025, $466.5 million in Q3 2025, and $634.8 million in Q2 2025.